L606 Inhalation System ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 86 | Pulmonary arterial hypertension | 1 |
86. Pulmonary arterial hypertension
Clinical trials : 1,181 / Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04041648 (ClinicalTrials.gov) | November 9, 2018 | 23/7/2019 | Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606 | A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dose of L606 for Inhalation in Healthy Subjects | Pulmonary Arterial Hypertension | Drug: L606 (Liposomal Treprostinil) Inhalation Solution 51ug;Device: L606 Inhalation System;Other: Placebo Solution | Pharmosa Biopharm Inc. | PPD | Recruiting | 18 Years | 50 Years | All | 64 | Phase 1 | United States |